Joel Savage en Communications and journalism, Healthcare, Writers Freelance Journalist, writer and author • A MIXTURE OF PERIODICALS 20/11/2016 · 2 min de lectura · +300



An Ebola victim in a body bag

"Symptom-less, Ebola exists and can hide in yourself, your family, neighbour or stranger and can never be detected until the virus mutates into symptomatic Ebola."

When hibernated Ebola mutates with recognizable symptoms, it will probably be more contagious than ever before and even become aerosol then the box of Pandora fully opens.

"The danger is real. Ebola is a disease that can survive in the animal population. So, as long as there are animals in the forests that are carrier of the disease, there will be Ebola in the region and therefore it can come back to the human population."

"In fact, we are planning against, let’s say, a 50-50 chance of Ebola coming back over the next 12 to 18 months, as it has done [in the past] in the Democratic Republic of the Congo (DRC) and as it has done in Uganda." - Peter Graaf: Special Representative and Head of the United Nations Mission for Ebola Emergency Response (UNMEER).


This document reveals evidence and scientific arguments how and why the Ebola Attack Team’s efforts and approach to battle Ebola was successful and justifiable. It proofs that it was common knowledge in the international health circles who purposely denied ten thousands of Ebola effected victims access to assumable protection and endangered the world population. 

Instead of supporting they denied, ignored, indoctrinated, intimidated and threatened to promote the development of specific experimental drugs to the benefit of the pharmaceutical industry. Their experimental drugs had no other effect than side effects but still W.H.O. continued its tunnel vision to sluice hundreds of millions of dollars to the pharmaceutical industry. 

This lack of empathy probably caused the death of ten thousand innocent Ebola patients, and 10,000 Ebola survivors are still suffering. How many more have to die before W.H.O. opens its eyes? The devastating effect on the regional collapsed economy also goes on their account, and the governments of Guinea, Liberia and Sierra Leone, should claim them for a compensation of least $5 billion each to recover from their incompetence, and to protect the world against new possible outbreaks. 


A group of humanitarians, including dedicated individuals from various background successfully introduced existing FDA approved oral medicines proven to have aided curing 300 Ebola patients in Sierra Leone in 2014. Between August 2015 and today, the same medicines have also been successfully administered to 100 Ebola Survivors suffering from symptom-less Post Ebola Syndrome complications. 

With support from the Concordia Medical and Dr. Montgomery Harding (Sierra Leone), the group has tried everything within the limit of its power to convince the international medical community, health authorities and media about the results and the possibility to compassionately medicate and protect Ebola patients, health care workers, burial teams and Ebola survivors with a medicine-protocol proposed by Dr. David Fedson (USA), Dr. Steven Opal (USA), and Dr. Ole Martin Rordam (Norway). 

Instead of support, the World Health Organization and allies ignored and scorned the humanitarian group, simply known as Ebola Attack Team (EAT) and refused to assist them and Dr. Harding to distribute and implement the proven treatment. Under intimidation and indoctrination of W.H.O., health organizations and the national health authorities refused to listen to, or study the arguments presented by EAT and Dr. Harding.

In 2012 the US Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, MD, USA, and Integrated Research Facility Frederick, National Institute of Allergy and Infectious Diseases,  National Institutes of Health, Fort Detrick, Frederick, MD, USA concluded that:

The cholesterol transporter, Niemann-Pick C1 (NPC1), is a recently discovered requirement for  EBOV entry into cells and is expressed by all cells. 17,24 It is possible that cells express varying  levels of NPC1, and this may alter susceptibility to infection. This is a focus of future research  that may uncover distinct ways to prevent and treat EBOV infections.

REMARK: Cholesterol is treated with STATINS like Atorvastatin


In early August 2014, Dr. David Fedson wrote to the Ebola staff at WHO (Bruce Aylward, Keiji Fukuda, Marie-Paule Kieny), urging them to include generic drugs (Atorvastatin & Irbesartan) among the Ebola treatments that would be tested in West Africa. WHO rejected his suggestion, and instead recommended testing agents that target only the virus and opposed the idea of treating the host response. 

They argued that the use of such drugs could increase viral replication and worsen the disease. But several studies have shown that statins actually reduce viral replication in human diseases like hepatitis C and improve clinical outcomes. Estrogen Receptor Modulators have been reported to be active in BSL-4 infectious Ebola virus replication assays and in animal model studies.

In the ensuing months, Fedson and colleagues (Dr. Steven Opal and Dr. Ole Martin Rordam) continued trying to interest health officials at WHO and the staffs at The Bill and Melinda Gates Foundation and The Welcome Trust to support studies of this approach to Ebola treatment. 

Read more: